Внутренние болезни
938 статей · 31 журналов
Журналы подкатегории (31)
- Kidney Medicine · Elsevier (87)
- European Journal of Internal Medicine · Elsevier (84)
- Canadian Journal of Diabetes · Elsevier (83)
- International Journal of Cardiology Cardiovascular Risk and Prevention · Elsevier (79)
- JHEP Reports · Elsevier (79)
- Internal Medicine Journal · Wiley (72)
- Journal of Diabetes Investigation · Wiley (71)
- Diabetes Research and Clinical Practice · Elsevier (68)
- Médecine des Maladies Métaboliques · Elsevier (61)
- La Revue de Médecine Interne · Elsevier (58)
- Atherosclerosis Plus · Elsevier (42)
- The Lancet Diabetes & Endocrinology · Elsevier (42)
- American Journal of Medicine Open · Elsevier (31)
- Journal of Internal Medicine · Wiley (24)
- Journal of General and Family Medicine · Wiley (15)
- Journal of Diabetes and its Complications · Elsevier (13)
- Diabetes & Metabolic Syndrome: Clinical Research & Reviews · Elsevier (11)
- Nutrition Clinique et Métabolisme · Elsevier (10)
- Journal of Human Hypertension · Springer Nature (8)
- Current Diabetes Reports · Springer Nature (0)
- Current Hypertension Reports · Springer Nature (0)
- Current Obesity Reports · Springer Nature (0)
- Diabetes Therapy · Springer Nature (0)
- Diabetologia · Springer Nature (0)
- Diabetology International · Springer Nature (0)
- Internal and Emergency Medicine · Springer Nature (0)
- International Journal of Diabetes in Developing Countries · Springer Nature (0)
- Journal of General Internal Medicine · Springer Nature (0)
- Journal of Rare Diseases · Springer Nature (0)
- Journal of Ultrasound · Springer Nature (0)
- Medizinische Klinik - Intensivmedizin und Notfallmedizin · Springer Nature (0)
- Dyslipidemia and Diabetic Macular Edema: A Systematic Review of Pathogenic Roles and the Effect of Lipid-lowering Therapies
- Inhibition of GDF15 Protects Mice From Developing Diabetes and HPA-Axis Dysfunction
- Acute Morning Versus Afternoon Exercise Differentially Affects Postprandial Fatty Acid Fluxes in Lean Tissues in Prediabetes: TIMED Consortium Study
- Time in Range and in Very High Range, but Not Glycemic Variability, are Associated With Diabetes Distress and Quality of Life Among Adolescents With Type 1 Diabetes
- New genomic understanding and challenges in clinical care of Turner syndrome
- Diabetes and the role of primary care: a global perspective
- IL-2 and immunoregulatory therapies in newly diagnosed type 1 diabetes
- Efficacy and safety of low-dose IL-2 in people with newly diagnosed type 1 diabetes (DIABIL-2): a double-blind, multicentre, randomised, placebo-controlled, phase 2b trial
- Diabetes in a warming world
- Redrawing the lines for the management of obesity in Asia
- Type 2 diabetes management: weekly combination therapy comes of age?
- Safety and tolerability of orforglipron in Japanese people with type 2 diabetes
- Less can be more: the 2026 Endocrine Society Guideline for precision care in central precocious puberty
- Time for personalised incretin titration
- Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial
- Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis
- Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial
- Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial
- Type 1 diabetes in older populations
- Hashimoto's thyroiditis: two decades on
- Multidisciplinary care of pituitary adenomas
- The development of obesity pharmacotherapy: from early challenges and setbacks to recognition by WHO
- Iodine in the UK: the end of an “accidental public health triumph”
- Oral small-molecule GLP-1 receptor agonist for obesity in people from Japan
- Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial
- Who should prescribe obesity management medications? An IFSO position statement
- Clinical and metabolic subtypes of recent-onset adult type 1 diabetes: a prospective cohort study
- Safeguarding paediatric metabolic health
- The glucagon renaissance in obesity therapeutics
- What Mauritius teaches us about diabetes surveillance